))
Chris Nowinski is a former football player at Harvard University and professional wrestler with WWE, World Wrestling Entertainment. After enduring a career-ending head injury, Chris has dedicated his professional life to serving patients and families affected by brain trauma, particularly Chronic traumatic encephalopathy, or CTE, a progressive neurodegenerative disease that develops after repeated head injuries. Jay and Chris discuss the state of head injuries in American athletics, the difference between advocating for head safety at youth and professional levels, Chris’ newest research, and much more. Episode Chapters (00:00) Intro (00:50) changes in the culture around concussions in the past two decades (02:39) padded helmet technology (03:55) concussion reporting in the NFL (10:35) Chris’ career path and concussion history (14:52) connecting with activists who haven’t themselves suffered a traumatic brain injury (17:42) SHAAKE - a new sign to identify concussions (20:53) Unions can help players advocate for safety policies (23:10) final thoughts and goodbye For video episodes, watch on www.youtube.com/@therudermanfamilyfoundation Stay in touch: X: @JayRuderman | @RudermanFdn LinkedIn: Jay Ruderman | Ruderman Family Foundation Instagram: All About Change Podcast | Ruderman Family Foundation To learn more about the podcast, visit https://allaboutchangepodcast.com/…
By Jason L. Crowell, MD Jerome H. Grossman MD Graduate Fellow, Harvard Kennedy School Neurologist, Beth Israel Deaconess Medical Center; Steve Pearson, Founder and President, ICER, Lecturer, Department of Population Medicine, Harvard Medical School
…
continue reading
1
How doctors can be a part of the solution
16:20
16:20
پخش در آینده
پخش در آینده
لیست ها
پسندیدن
دوست داشته شد
16:20
What can physicians do in their hospitals and communities to advocate for fair drug prices? What questions should we ask our patients to assess for financial toxicity? In the final episode of the season, we discuss the steps doctors can be taking now to help solve the drug pricing problem.توسط instituteforclinicalandeconomicreview
…
continue reading
1
What else makes a drug “valuable”?
20:14
20:14
پخش در آینده
پخش در آینده
لیست ها
پسندیدن
دوست داشته شد
20:14
If we only look at the benefits that a drug provides to those patients who take it, we may underestimate its value by ignoring the benefits it provides to the broader healthcare system. In episode 7, we reveal some of the other reasons that can make a drug more valuable than first meets the eye.توسط instituteforclinicalandeconomicreview
…
continue reading
If a “fair” price rewards the benefit a drug provides, how do we quantify those benefits—both to the patient and, more broadly, to society? Cost-effectiveness analysis is the tool we can use to quantify a drug’s benefit in a way that can be compared across treatments.توسط instituteforclinicalandeconomicreview
…
continue reading
1
Who sets a drug’s price, and how do we know it’s fair?
22:22
22:22
پخش در آینده
پخش در آینده
لیست ها
پسندیدن
دوست داشته شد
22:22
In episode 5, we review the variety of approaches one might take to settle on what the “fair” price of a drug should be. The most logical solution to this problem is to price the value—set a drug’s price commensurate with the clinical benefits it provides.توسط instituteforclinicalandeconomicreview
…
continue reading
1
What’s in it for me? Incentives for making new drugs
27:24
27:24
پخش در آینده
پخش در آینده
لیست ها
پسندیدن
دوست داشته شد
27:24
What motivates a drug manufacturer to create a drug in the first place? How do firms stretch the limits of these incentives? In episode 4, we discuss how the “ecosystem” of drug development in the US has led to truly remarkable innovation but also runaway drug prices.توسط instituteforclinicalandeconomicreview
…
continue reading
1
From Pharma to the Medicine Cabinet: Who Manages the Drugs?
25:23
25:23
پخش در آینده
پخش در آینده
لیست ها
پسندیدن
دوست داشته شد
25:23
Drugmakers, pharmacies, wholesale distributors, physicians, pharmacy benefit managers—the world of prescription drugs can seem extraordinarily complex. In episode 3, we disentangle this spider’s web and answer the question: who decides how much our patients pay at the pharmacy?توسط instituteforclinicalandeconomicreview
…
continue reading
Whenever we choose to spend on one thing instead of another, we pay an opportunity cost. And, just like in life, healthcare is an either/or decision. Patients face decisions about how to spend their money on healthcare, just like insurance companies and governments must decide how to spend their finite dollars on healthcare.…
…
continue reading
In the first episode of the series, we discuss the problem of skyrocketing drug prices and the harmful effects they have on our patients. Not only must patients decide what their medications are worth to them, but payers introduce barriers that limit patients’ access to care. More broadly, we also review the ways that drug prices affect all of our …
…
continue reading
In a new podcast series from the Institute for Clinical and Economic Review (ICER), neurologist Dr. Jason Crowell sits down with ICER’s President Dr. Steve Pearson to pry open the black box of US drug pricing and to wrestle with each of the financial and ethical tensions that undergird our current medical infrastructure. A must-listen for physician…
…
continue reading
